Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy Vollmer

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
The Lancet. Neurology|February 19, 2010
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon betaDaniel Wynn, Michael Kaufman, Xavier Montalban, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimatesJonathan D Campbell, Vahram Ghushchyan, R Brett McQueen, et al.
Cell Death & Disease|April 8, 2023
Multiple sclerosis plasma IgG aggregates induce complement-dependent neuronal apoptosisWenbo Zhou, Michael Graner, Petr Paucek, et al.
Plos One|February 22, 2020
Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptidesMichael Graner, Tiffany Pointon, Sean Manton, et al.
Annals of Neurology|March 23, 2011
Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammationJunwei Hao, Denise Campagnolo, Ruolan Liu, et al.
Journal of the Neurological Sciences|October 24, 2019
Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-upBrandi Vollmer, Daniel Ontaneda, Haleigh Harris, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|May 4, 2021
Aberrant Immunoglobulin G Glycosylation in Multiple SclerosisPeter G E Kennedy, Michael Graner, Tiffany Pointon, et al.
Annals of Neurology|October 23, 2009
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trialKathleen Hawker, Paul O'Connor, Mark S Freedman, et al.
The New England Journal of Medicine|February 15, 2008
B-cell depletion with rituximab in relapsing-remitting multiple sclerosisStephen L Hauser, Emmanuelle Waubant, Douglas L Arnold, et al.
Neurology. Clinical Practice|August 25, 2018
Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centersBrandi Vollmer, Daniel Ontaneda, Anasua Bandyopadhyay, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
The Lancet. Neurology|February 19, 2010
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon betaDaniel Wynn, Michael Kaufman, Xavier Montalban, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimatesJonathan D Campbell, Vahram Ghushchyan, R Brett McQueen, et al.
Cell Death & Disease|April 8, 2023
Multiple sclerosis plasma IgG aggregates induce complement-dependent neuronal apoptosisWenbo Zhou, Michael Graner, Petr Paucek, et al.
Plos One|February 22, 2020
Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptidesMichael Graner, Tiffany Pointon, Sean Manton, et al.
Annals of Neurology|March 23, 2011
Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammationJunwei Hao, Denise Campagnolo, Ruolan Liu, et al.
Journal of the Neurological Sciences|October 24, 2019
Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-upBrandi Vollmer, Daniel Ontaneda, Haleigh Harris, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|May 4, 2021
Aberrant Immunoglobulin G Glycosylation in Multiple SclerosisPeter G E Kennedy, Michael Graner, Tiffany Pointon, et al.
Annals of Neurology|October 23, 2009
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trialKathleen Hawker, Paul O'Connor, Mark S Freedman, et al.
The New England Journal of Medicine|February 15, 2008
B-cell depletion with rituximab in relapsing-remitting multiple sclerosisStephen L Hauser, Emmanuelle Waubant, Douglas L Arnold, et al.
Neurology. Clinical Practice|August 25, 2018
Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centersBrandi Vollmer, Daniel Ontaneda, Anasua Bandyopadhyay, et al.
Pageof 8